IP Library Granted Patent US 10,765,683
Granted Patent B2
US 10,765,683 · App. 14/812,515 · Granted Sep 8, 2020

Stable formulations for parenteral injection of small molecule drugs

Inventors: Steven J. Prestrelski (San Diego, CA); Nancy Scott (Chicago, IL)
Assignee: Xeris Pharmaceuticals, Inc.
A61K31/5513A61K9/0019A61K9/08A61K31/137A61K31/167A61K31/352A61K31/4045A61K31/4196A61K31/496A61K31/55A61K31/675A61K31/7036A61K47/10A61K47/14A61K47/20A61K47/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,765,683
App. No.
14/812,515
Granted
Sep 8, 2020
Kind
B2
Abstract

Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.

Claims (17)

1. A parenteral injection device comprising:

an injection device containing an injectable composition comprising:

(a) a dimethylsulfoxide (DMSO) solvent; and

(b) a benzodiazepine, or a salt thereof, solubilized within the solvent, wherein the benzodiazepine is present in the injectable composition in an amount up to its solubility limit, wherein the benzodiazepine consists of diazepam,

wherein the injectable composition comprises less than 5% by weight residual water, and the volume of the injectable composition to be parenterally injected is 3 ml or less.

2. The injection device of claim 1 , wherein the injection device is a syringe, a pen injection device, an auto-injector device, an external or implantable pump, or a perfusion bag.

3. The injection device of claim 1 , wherein the injectable composition comprises 50 mg/ml to 300 mg/ml of diazepam.

4. The injection device of claim 1 , wherein the volume of the injectable composition to be parenterally injected is from 0.1 μl to 1 μl.

5. The injection device of claim 1 , wherein the volume of the injectable composition to be parenterally injected is from 1 μl to 10 μl.

6. The injection device of claim 1 , wherein the volume of the injectable composition to be parenterally injected is from 10 μl to 1 ml.

7. The injection device of claim 1 , wherein the volume of the injectable composition to be parenterally injected is from 1 ml to 3 ml.

8. A method of using the injection device of claim 1 to a subject, the method comprising parenterally injecting the injectable composition to the subject.

9. The method of claim 8 , wherein the injectable composition is parenterally injected with a syringe, a pen injection device, an auto-injector device, an external or implantable pump, or a perfusion bag.

10. The method of claim 8 , wherein the injectable composition is not diluted prior to administration.

11. A method of treating anxiety, muscle spasms, or seizures, the method comprising parenterally injecting the injectable composition using the injection device of claim 1 to a subject in need thereof.

12. The method of claim 11 , wherein the injectable composition is parenterally injected with a syringe, a pen injection device, an auto-injector device, an external or implantable pump, or a perfusion bag.

13. The method of claim 11 , wherein the injectable composition is not diluted prior to administration.

Assignments (4)
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Mar 10, 2022
From: OXFORD FINANCE LLC
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 059358/0700 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →
SECURITY INTEREST Recorded Sep 12, 2019
From: XERIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050362/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2016
From: PRESTRELSKI, STEVEN; SCOTT, NANCY
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 037733/0532 →